An insufficient response rate to PE in patients with NEN G3 and proliferation rate (Ki67) < 55%, irrespective of the morphological classification, was first reported in the Nordic NEC trial [16]. The gene discussed is MKI67; the disease is neuroendocrine carcinoma.